

1 **Clinical Characteristics and Factors Associated with Long COVID in Zambia, August 2020 to January**  
2 **2023**

3 **Authors:** Warren Malambo<sup>1,\*</sup>, Duncan Chanda<sup>2</sup>, Lily Besa<sup>2</sup>, Daniella Engamba<sup>2</sup>, Linos Mwiinga<sup>1</sup>, Mundia  
4 Mwitumwa<sup>2</sup>, Peter Matibula<sup>2</sup>, Neil Naik<sup>2</sup>, Suilanji Sivile<sup>2</sup>, Simon Agolory<sup>1</sup>, Andrew Auld<sup>1</sup>, Lloyd  
5 Mulenga<sup>2</sup>, Jonas Z. Hines<sup>4,†</sup>, Sombo Fwoloshi<sup>2,3,†</sup>

6 **Affiliations:**

7 <sup>1</sup> U.S. Centers for Disease Control and Prevention, Division of Global HIV/TB, Lusaka, Zambia

8 <sup>2</sup> Ministry of Health, Lusaka, Zambia

9 <sup>3</sup> University Teaching Hospital Adult and Emergency Hospital, Department of Internal Medicine, Lusaka,  
10 Zambia

11 <sup>4</sup> U.S. Centers for Disease Control and Prevention, Division of Global Health Protect, Nairobi, Kenya

12

13 \* Corresponding author: Warren Malambo

14 Centers for Disease Control and Prevention, Zambia.

15 Email: ykh1@cdc.gov

16 Phone: +260 961 640 948

17

18 † These authors contributed equally

19

20 **Keywords:** COVID-19, Long COVID, post-acute COVID-19, persistent symptoms, Zambia

21

22 **Word count**

23 Abstract: 300

24 Manuscript: 2,943

25

26 **ABSTRACT**

27 **Background**

28 Several seroprevalence studies in Africa documented the extent of spread of SARS-CoV-2, yet there is  
29 limited data on signs, symptoms and conditions that continue or develop after acute COVID-19 infection  
30 (long COVID). We sought to examine patient characteristics at post-acute COVID-19 (PAC-19) clinics in  
31 Zambia and assess factors associated with long COVID at first visit to a PAC-19 clinic and longitudinally  
32 among a cohort of patients.

33 **Methods**

34 Long COVID was defined, initially in the Zambia PAC-19 clinical guidelines, as new, relapsing or persistent  
35 symptoms lasting >4 weeks after an initial SARS-CoV-2 infection. Severe illness was defined as COVID-19  
36 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with  
37 steroids/remdesivir. We fitted logistic regression models with cross-sectional and longitudinal data and  
38 considered statistical significance at  $p < 0.05$ .

39 **Results**

40 In total, 1,359 patients attended PAC-19 clinics and had data abstracted from Aug-2020 to Jan-2023; 548  
41 (40.3%) patients with  $\geq 2$  visits were included in the longitudinal analysis. Patients' median age was 53  
42 (interquartile range [IQR]: 41-63) years, 919 (67.6%) were hospitalized for acute COVID-19, and of whom  
43 686 (74.6%) had severe illness. Patients with hospital length of stay  $\geq 15$  days (adjusted odds ratio [aOR]:  
44 5.50; 95% confidence interval [95% CI]: 3.06-10.3), severe illness (aOR: 3.23; 95% CI: 1.68-6.75), and  
45 comorbidities (aOR: 1.51; 95% CI: 1.04-2.22) had significantly higher odds of long COVID. Longitudinally,  
46 long COVID prevalence significantly ( $p < 0.001$ ) declined from 75.4% at the first PAC-19 visit to 26.0% by  
47 the fifth visit. The median follow-up time was 7 (IQR: 4-12) weeks.

48 **Conclusion**

49 Long COVID symptoms were common among patient presenting for care in PAC-19 clinics in Zambia, but  
50 most recovered within  $\sim 2$  months. Despite potentially substantial morbidity due to long COVID, few  
51 patients overall with COVID-19 attended a PAC-19 clinic. Scaling up PAC-19 services and integrating into  
52 routine clinical care could improve access by patients.

53

## **INTRODUCTION**

Following acute COVID-19, some individuals experience a variety of symptoms and conditions that continue or develop after acute COVID-19 infection, a syndrome commonly referred to as long COVID (1, 2). Commonly reported long COVID symptoms include fatigue, fever, cough, dizziness, brain fog, and myalgia although symptoms are varied and potentially have overlapping etiologies (3-5). Long COVID is a syndrome characterized by persistent, new, relapsing or delayed SARS-CoV-2 symptoms  $\geq 12$  weeks beyond onset of the acute episode (1, 6-8), and can have a protracted path to recovery that impacts quality of life, earnings and health care costs (9-11).

There is limited evidence on long COVID from countries in Africa (12). Disease severity and admission to the intensive care unit (ICU) during acute COVID-19, for example, were found to be associated with long COVID in Nigeria and South Africa (13, 14). In Zambia, 17% of persons with acute COVID-19 in July 2020 were found to be experiencing symptoms  $\sim 2$  months later (15). Zambia's experience on the COVID-19 pandemic, however, is characterized by high numbers of SARS-CoV-2 infections despite relatively low numbers of confirmed COVID-19 cases (16).

While dozens of seroprevalence studies in Africa document the extent of spread of SARS-CoV-2, few have examined longer term outcomes such as long COVID (14, 17). This is an important gap given the estimated prevalence of long COVID and extent of SARS-CoV-2 transmission in Africa. In this study, we examined the characteristics of patients presenting in specialized post-acute COVID-19 (PAC-19) clinics in Zambia. We further assessed factors associated with long COVID at first visit to a PAC-19 clinic and longitudinally among a cohort of patients with  $\geq 2$  PAC-19 clinic visits.

## **METHODS**

### ***Study sites***

Beginning August 2020, the Zambia Ministry of Health set up 13 specialized PAC-19 clinics to care for people following SARS-CoV-2 infection, initially at the University Teaching Hospital and Levy Mwanawasa Teaching Hospital in Lusaka city (the capital) and subsequently at other hospitals (Lewanika Referral Hospital [January 2021], Choma District Hospital [March 2021], Livingstone General Hospital [March 2021], Kabwe General Hospital [April 2021], Ndola Central Hospital [June 2021], Chipata Central Hospital [July 2021], Kitwe Central Referral Hospital [July 2021], Chinsali District Hospital [August 2021], Solwezi General Hospital [August 2021], Kasama General Hospital [September 2021], and Mansa General Hospital [September 2021]). Per national PAC-19 clinical guidelines, patients diagnosed with SARS-CoV-2 infection presented in PAC-19 clinics for follow-up care after discharge from hospital admission or outpatient episodic (18).

### ***PAC-19 clinics***

At the first PAC-19 clinic visit, patients' demographics, medical history, comorbidities, and current symptoms were recorded on a standardized paper form. Physical examinations and laboratory investigations were conducted based on patient's medical history as required. Patients' ability to perform activities, as part of examination of their functional and mental health status, were also evaluated. Further clinical appointments (up to 5 review visits) were at the clinicians' discretion, and patients requiring further specialists care were referred to various units including physiotherapy, cardiology, endocrinology, nephrology, psychiatry, and pulmonology. Anonymized data from the standardized form was abstracted into an electronic database (REDCap v11.0.3), which was accessed on 5<sup>th</sup> January 2023 and analyzed for this study.

### ***Ethical Considerations***

This retrospective study was preconceived during the development of clinical and operational guidelines for the management of PAC-19 patients in Zambia. The study obtained ethical clearance (waiver for informed consent) from the University of Zambia Biomedical Research Ethics Committee (Ref No. 2711-2022), approval from the Zambia National Health Research Authority (Ref No: NHRA0002/26/05/2022) and was determined to be non-research according to the U.S Centers for Disease Control and Prevention (CDC) policy and applicable federal law (See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. 552a; 44 U.S.C.3501 et seq.). CDC investigators did not interact with the patients or have access to personally identifiable information but participated in protocol development and analysis of anonymized data.

### ***Definition of key variables and terminologies***

Long COVID was defined initially in the Zambia post-acute COVID-19 guidelines as new, relapsing or persistent symptoms that lasted greater than 4 weeks after the initial SARS-CoV-2 infection (18, 19). Symptoms were assessed at each PAC-19 clinic visit on review of systems: general, cardiovascular, pulmonary, urinary, neurologic, musculoskeletal, ear, nose, and throat (ENT), mental health concerns, depression, anxiety, and dermatologic. Pre-existing comorbidities (hypertension, diabetes, cardiovascular disease, cancer, chronic lung disease, kidney disease, or liver disease, immunosuppression, obesity, HIV and TB) were documented. Diabetes, hypertension, or deep vein thrombosis/pulmonary embolism detected at the time of SARS-CoV-2 diagnosis were categorized as newly diagnosed medical conditions.

Severe illness was defined as COVID-19 episode that required supplemental oxygen therapy, intensive care unit (ICU) stay or treatment with steroids or remdesivir. Vaccination status categorization was

based on vaccination records, when available, or patients' self-reported status. SARS CoV-2 variants classification was based on the dominant variant at the time of SARS-CoV-2 diagnosis as captured by the Zambia's genomic surveillance system and submitted to the Global Initiative on Sharing All Influenza Data (GISAID) rather than sequenced specimens from patients (20).

### ***Statistical Analysis***

We first performed a cross-sectional analysis of all PAC-19 clinic patients in Zambia entered in the electronic databases from August 5, 2020, through to January 26, 2023, and then did a cohort sub-analysis of patients with  $\geq 2$  PAC-19 clinic visits. The cross-sectional analysis focused on the descriptive statistics of the demographic and clinical characteristics of PAC-19 patients. Logistic regression models were fitted to assess for factors associated with having long COVID at first visit to a PAC-19 clinic.

The main cross-sectional analysis was for patients hospitalized during acute COVID-19 (inpatients) to maintain key variables in the analysis. At multivariable analysis, we adjusted for age, presence of newly diagnosed medical conditions, presence of pre-existing comorbidities, and COVID-19 episode details (i.e., hospital length of stay, and presence of severe illness). Covariate inclusion criteria at multivariable analysis were based on theoretical relevance to the study and statistical significance ( $p\text{-value} \leq 0.2$ ). We also conducted an additional cross-sectional analysis that included all patients (both inpatients and outpatients during acute infection) to assess for the association of hospitalization with long COVID.

For the cohort study (patients with 2 to 5 PAC-19 clinic visits), the data structure included repeated observations of the outcome variable, and patient-level characteristics that might longitudinally be associated with the long COVID outcome. The demographic and clinical factors included time-invariant covariates (sex, age [each patient observed for  $<1$  year], presence of newly diagnosed medical conditions, presence of pre-existing comorbidities, and acute COVID-19 episode details) and time-variant covariates (COVID vaccination status and referral to specialist services).

We fitted logistic regression models for longitudinal data to account for the heterogeneity in long COVID outcome by adjusting for between PAC-19 clinic visits fixed effects (i.e., the observation occasions which were constant across patients within visits) and patients-level fixed effects (demographic and clinical covariates which were constant within a patient at each visit). PAC-19 clinic visits fixed effects estimated the marginal association of covariates with the long COVID outcome whereas patients-level fixed effects estimated the patient-specific characteristics association with long COVID. Unadjusted and adjusted models with longitudinal data were fitted for acute COVID-19 inpatients only and an additional analysis for all patients. The patient was the cluster variable for the models. We reported odds ratios with the

95% confidence interval (95% CI) from the models. Since there was dependence in the data, we also reported the conditional intraclass correlation (ICC). The ICC quantified the variance in long COVID outcome that was attributable to between patients and within patient differences across visits.

Only covariates with <10% missingness were included at multivariable analyses. To assess for bias, we checked for the proportion of listwise deletion when covariates of interest with >10% missingness were included in the models. Model selection was based on goodness-of-fit statistics (i.e., adjusted pseudo  $R^2$ , Akaike information criteria, Bayesian information criteria and log-likelihood value). Analysis was done in R software version 4.3.1 (R Foundation for Statistical Computing) and statistical significance was considered at  $p < 0.05$ .

## RESULTS

In total, 1,359 patients attended PAC-19 clinics from August 2020 to January 2023 with data entered in the electronic database were included in the analyses (Figure 1). Of these patients, 548 (40.3%) had  $\geq 2$  PAC-19 clinic visits and were included in the longitudinal analysis. Most patients (919/1,087, 84.5%) were hospitalized during acute COVID-19 (Table 1). Overall, patients' median age was 53 years (interquartile range [IQR]: 41-63 years), and 693 (52.9%) were female. Most patients (58.0%) were from Lusaka, where the first two PAC-19 clinics were initially set up. Nearly half of the patients (46.9%) were diagnosed with COVID-19 when delta was the dominant variant (Figure 2).

At baseline, 654 (48.1%) patients overall, reported any pre-existing comorbidity. Among these patients, hypertension ( $n=465$ , 71.1%), diabetes ( $n=172$ , 26.3%), HIV ( $n=165$ , 25.2%) and cardiovascular disease ( $n=73$ , 11.2%) were commonly ( $\geq 10\%$ ) reported (supplementary Table 1). One hundred nineteen (8.8%) patients had been diagnosed with new medical conditions at the time of SARS-CoV-2 diagnosis. Of these patients, hypertension and diabetes were detected at SARS-CoV-2 diagnosis in 68 (53.8%) and 64 (53.8%) patients, respectively.

Among the acute COVID-19 episode hospitalized patients, the median length of stay was 7 days (IQR: 4-15 days). Of these inpatients, 686 (74.6%) were categorized as having had severe illness. The medium time from the date of COVID-19 diagnosis to when patients presented for care in a PAC-19 clinic was 4 weeks (IQR: 2-6 weeks). At first visit to a PAC-19 clinic, 274 (29.8%) hospitalized patients had long COVID. Among these long COVID patients, commonly reported symptoms included cough (38.7%), fatigue (38.5%), shortness of breath (26.5%), chest pain (20.9%), headache (14.8%), muscles aches/pain (14.1%), palpitations (12.5%), joint aches/pain (11.9%), and forgetfulness or brain fog (8.0%). Among the

outpatients, 103 (23.4%) had long COVID bringing the overall number of long COVID patients to 377 (27.7%).

Among all patients, 232 (28.9%) patients had worse or same (limitations in daily activities) functional status since acute COVID-19. The functional status patients commonly reported difficulty in undertaking was walking long distances greater than 1km (22.6%), day-to-day work/school (cognitive) activities (19.4%), standing for  $\geq 30$  minutes (19.4%), taking care of household tasks (17.8%), and self-care (activities like bathing and dressing) – 15.1%. Fifty-nine (6.6%) patients were referred to specialist care, including cardiology (35.6%), endocrinology (33.9%), psychiatry (25.4%), pulmonology (18.6%), physiotherapy (11.0%), and nephrology (1.7%). Overall, 243 (23.5%) patients had been vaccinated before being diagnosed with SARS-CoV-2, representing 28.5% of patients seen at PAC-19 clinics from April 2021 when COVID-19 vaccines first became available in Zambia.

Hospital length of stay of 8-14 days and  $\geq 15$  days were associated with significantly higher odds of long COVID (adjusted odds ratio [aOR]: 1.97; 95% confidence interval [CI]: 1.07-3.72, and aOR: 5.5; 95% CI: 3.06-10.3, respectively) - (Table 2). Patients with pre-existing comorbidities (aOR: 1.51; 95% CI: 1.04-2.22) and those who had severe illness (aOR: 3.23, 95% CI: 1.68-6.75) were associated with significantly higher odds of long COVID. Independently, vaccinated patients had non-significant reduced likelihood of long COVID (OR: 0.94; 95% CI: 0.64-1.36) and those who were referred to specialist services had a 1.88-fold (OR: 1.00-3.48, p-value=0.045) increased likelihood of long COVID. In the additional cross-sectional analysis of all patients, inpatients compared to outpatients were not associated with long COVID (aOR: 1.06; 95% CI: 0.73-1.55) (Supplemental Table 2).

For inpatients in the longitudinal analysis, the overall median time patients presented at a PAC-19 clinic was 7 weeks (IQR: 4-12 weeks) (Supplemental Figure 1). Longitudinally, the most frequently reported long COVID symptoms ( $\geq 5\%$  at any PAC-19 clinic visit) were cough (16.9%), fatigue (16.4%), shortness of breath (10.6%), chest pain (8.4%), headache (8.3%), palpitations (6.6%) and muscle aches/pains (5.2%), and forgetfulness (3.0%) (Figure 3). The prevalence of long COVID significantly declined ( $p < 0.001$ ) from 75.4% at the first PAC-19 clinic visit to 53.5% at the second visit, 59.8% at the third visit, 49.6% at the fourth visit, and 26.0% at the final visit (Supplemental Table 3).

We found similar associations with long COVID in the longitudinal analysis as the cross-sectional analysis for patients with hospital length of stay of  $\geq 15$  days and severe illness (aOR: 4.26; 95% CI: 1.52-12.0, and aOR: 1.92; 95% CI: 1.03-3.56, respectively). The conditional ICC was 0.57, suggesting that 57% of the longitudinal variance in long COVID was attributed to between patient differences. Similar associations

were also observed in the longitudinal secondary analysis of all patients for the presence of pre-existing comorbidities and hospitalization status during acute COVID-19 episode (aOR: 1.76; 95% CI: 1.08-2.88, and aOR: 0.35; 95% CI: 0.04-2.90, respectively).

## **Discussion**

Long COVID symptoms were common among patients presenting for care in specialized post-acute COVID-19 clinics in Zambia, which could represent potential substantial morbidity from COVID-19 given the extent of infections in the country (21). However, most patients with long COVID recovered by two months. Few other studies have reported on long COVID from countries in Africa, which is an important gap in evidence. These findings, however, are from patients who self-presented in PAC-19 clinics and were a small fraction of the total number of persons with confirmed COVID-19 in Zambia. Other patients could have by-passed the PAC-19 clinic and presented directly to clinicians or specialist service depending on their symptoms.

Overall, we found that commonly reported long COVID symptoms in Zambia were similar to findings in other studies (13-15, 22). However, symptoms including forgetfulness (commonly reported among long COVID patients) and change in sleep were less commonly reported in our study compared to previous reports (7, 10). In the longitudinal analysis, we found that by the final PAC-19 clinic visit, nearly all patients who were not lost to follow up had their long COVID symptoms resolved. This is a strength of our study in that while previously studies have followed up patients at specific intervals such as at 2, 3, 6 or 12 months (10, 14, 15, 23-25), this study had individual patient follow up times which provides finer details of long COVID outcome in each interval of follow up.

Hospital length of stay of  $\geq 15$  days and the presence of pre-existing comorbidities, for example, were found to be associated with increased likelihood for long COVID. This is consistent with what is reported by other studies that patients with longer hospitalization stay for acute COVID-19 or have comorbidities were more likely to have long COVID symptoms (22, 26, 27). Similarly, we found that patients who had severe illness had increased odds for long COVID consistent with what has been found in Nigeria, South Africa and elsewhere (13, 14, 28).

In both the cross-sectional and longitudinal analysis, inpatient compared to outpatient care during COVID-19 episode were found to be associated with indistinguishable likelihood of long COVID. One reason for this might be that those who were outpatient and attending PAC-19 clinics were a special subset of outpatients with COVID-19 (i.e., they were seeking out or were referred for follow-up care during acute COVID-19e). Furthermore, inpatients (the majority of whom had severe illness) might have



been more likely to be referred to PAC-19 clinic whereas those who were outpatient were likely self-referral to PAC-19 clinic meaning only those who really needed it (i.e., those with ongoing symptoms) were in this study. This could be a form of selection bias within the sample and seems to be supported by a much smaller proportion of outpatients who were in the longitudinal study.

COVID-19 vaccines have been shown to be effective at preventing symptomatic SARS-CoV-2 infections and long COVID (29, 30). In this study, however, vaccinated patients failed to show significant protective association between COVID vaccination and long COVID. A possible explanation for this finding might be the heterogeneity in vaccination status during the study since Zambia only began offering COVID-19 vaccination in April 2021 (i.e., before the delta wave and ~8 months after patients began presenting for care in PAC-19 clinics) (31). For example, among the patients diagnosed with SARS-CoV-2 during the wild type and beta dominant variants periods, prior to publicly available COVID-19 vaccination in Zambia, only 1 patient ever reported being vaccinated.

The findings in this study are subject to several limitations. Firstly, only patients attending PAC-19 clinics were included in the study, so patients with long COVID who sought care elsewhere (or didn't seek care) were not included. This potentially presents some form of selection bias within the study. Furthermore, PAC-19 clinics took time to scale-up throughout Zambia and some persons might still have faced difficulty accessing them. Overall, fewer than 1% of the over 344,000 confirmed COVID-19 cases in Zambia as of January 2023 presented for care in PAC-19 clinics. Secondly, COVID-19 illness history (i.e., date of SARS-CoV-2 testing, hospitalization status, vaccination history, acute COVID-19 episode details, etc.) were self-reported by patients to clinicians which cannot rule out self-serving bias. Thirdly, the study utilized routinely collected clinical information from PAC-19 clinics which meant there was substantial missingness for some key variables; thus, some variables were not adjusted for at multivariable analyses to maintain sample size. And lastly, patients were not retested for SAR-CoV-2 infection at subsequent PAC-19 review visits and so the possibility of reinfection could not be ruled out.

Given the burden of COVID-19 in Zambia, the findings of a potentially substantial morbidity due to long COVID, and that yet few patients overall with COVID-19 had attended a PAC-19 clinic, scaling up PAC-19 care services and integrating into routine clinical care could improve access by patients and further aid in understanding the true burden of long COVID in Zambia. This could be coupled with efforts to expand knowledge of long COVID among clinicians and the general population in Zambia. Scaling of vaccination, may likely, provide better outcomes not only for long COVID but also during acute SARS-CoV-2 infection. Improving data quality for routine clinical data, could possibly be achieved by utilizing the existing

electronic health record in Zambia (SmartCare) for all clinical encounters. Information sharing between referral care services and PAC-19 clinics could aid in understanding the outcome of long COVID among patients requiring specialist care.

**CDC Disclaimer:** *The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention (CDC).*

**Author contribution statement:** *Warren Malambo, Duncan Chanda, Lily Besa, Daniella Engamba, Linos Mwiinga, Mundia Mwitumwa, Peter Matibula, Bob Chirwa, Neil Naik, Suilanji Sivile, Simon Agolory, Andrew Auld, Lloyd Mulenga, Jonas Z. Hines, and Sombo Fwoloshi developed the protocol for this study, designed data collection tools, and monitored data collection. Lily Besa, Duncan Chanda, Peter Matibula, Bob Chirwa, Neil Naik, Suilanji Sivile, Lloyd Mulenga, and Sombo Fwoloshi contributed to data curation. Warren Malambo, Lily Besa, Duncan Chanda, Jonas Z. Hine and Sombo Fwoloshi cleaned the data, while all authors contributed to development of the analysis plan. Warren Malambo analyzed the data (preliminary analysis) which was validated by Duncan Chanda, Jonas Z. Hines, and Sombo Fwoloshi. All authors drafted, reviewed, and revised the paper.*

**PEPFAR Funding Acknowledgment:** *This study has been supported in part by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC). Grant number/CoAg ID number: GH002234*

**Role of the funding source:** *The study sponsor or funder had no role, in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. In addition, there is independence of researchers from funders and all authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.*

**Data sharing statement:** *Data may be obtained by a third party and are not currently publicly available. The data are deidentified participant data, available with permission from the Government of the Republic of Zambia (GRZ) – Ministry of Health (MoH), [info@moh.gov.zm](mailto:info@moh.gov.zm). A request to access the data can be made to the corresponding author ([ykh1@cdc.gov](mailto:ykh1@cdc.gov)), who will need to get permission from GRZ (MoH) to avail the data. Protocols and statistical analysis information is available as per above.*

**Ethical approval statement:** *The study protocol was approved by the University of Zambia Biomedical Research Ethics Committee (Ref No. 2711-2022).*

## References

1. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *Jama*. 2023;329(22):1934-46.
2. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022;22(4):e102-e7.
3. Vahey GM, Marshall KE, McDonald E, Martin SW, Tate JE, Midgley CM, et al. Symptom Profiles and Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado, USA, 2020. *Emerging infectious diseases*. 2021;27(2):385-95.
4. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nature Medicine*. 2021;27(4):601-15.
5. Chippa V, Aleem A, Anjum F. *Post Acute Coronavirus (COVID-19) Syndrome*: StatPearls Publishing, Treasure Island (FL); 2021 2021.
6. Danesh V, Arroliga AC, Bourgeois JA, Boehm LM, McNeal MJ, Widmer AJ, et al. Symptom Clusters Seen in Adult COVID-19 Recovery Clinic Care Seekers. *J Gen Intern Med*. 2023;38(2):442-9.
7. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.
8. World Health Organization. Post COVID-19 condition (Long COVID) 2022 [Available from: <https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition>].
9. Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. *Jama*. 2020;324(6):603-5.
10. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet (London, England)*. 2021;397(10270):220-32.
11. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. *MMWR Morbidity and mortality weekly report*. 2020;69(30):993-8.
12. Nyasulu PS, Tamuzi JL, Erasmus RT. Burden, causation, and particularities of Long COVID in African populations: A rapid systematic review. *IJID Regions*. 2023;8:137-44.
13. Osikomaiya B, Erinoso O, Wright KO, Odusola AO, Thomas B, Adeyemi O, et al. 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. *BMC Infect Dis*. 2021;21(1):304.
14. Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. *Lancet Glob Health*. 2022;10(9):e1247-e56.
15. Zulu JE, Banda D, Hines JZ, Luchembe M, Sivile S, Siwingwa M, et al. Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September 2020: a cohort study. *The Pan African medical journal*. 2022;41:26.
16. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. *Lancet Global Health*. 2021;9(6):e773-e81.

17. Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. *BMJ Glob Health*. 2022;7(8).
18. Ministry of Health (Zambia). Clinical Guidance for Management of Patients with Coronavirus Disease 2019 (COVID-19) Lusaka2023 [Available from: [https://www.moh.gov.zm/?wpfb\\_dl=181](https://www.moh.gov.zm/?wpfb_dl=181)].
19. Ministry of Health. Clinical and Operational Guidelines for the Management of Post-Acute Covid-19 (PAC-19) Patients in Zambia. Lusaka: Ministry of Health (Zambia); 2022.
20. GISAID. EpiCov 2023 [Available from: <https://www.epicov.org/epi3/frontend#24d000>].
21. Elizabeth Heilmann TT, Felix Chilambe, Sombo Fwoloshi, Kalubi Kalenga, Mpanji Siwingwa, Samuel Yingst, Warren Malambo, Victoria Seffren, Ruchi Yadav, Theodora Savory, Andrew Auld, Jonas Hines, Lloyd B. Mulenga, Izukanji Sikazwe. SARS-COV-2 seroprevalence trend among pregnant women in Zambia, 2021-2022. Conference on Retroviruses and Opportunistic Infections (CROI); February 19-22, 2023; Seattle, Washington2023.
22. Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, Navarro-Santana M. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. *European Journal of Internal Medicine*. 2021;92:55-70.
23. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS Med*. 2021;18(9):e1003773.
24. Houben-Wilke S, Goërtz YM, Delbressine JM, Vaes AW, Meys R, Machado FV, et al. The Impact of Long COVID-19 on Mental Health: Observational 6-Month Follow-Up Study. *JMIR Ment Health*. 2022;9(2):e33704.
25. Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. *BMJ*. 2023;380:e072529.
26. Cirulli ET, Barrett KMS, Riffle S, Bolze A, Neveux I, Dabe S, et al. Long-term COVID-19 symptoms in a large unselected population. *medRxiv*. 2020:2020.10.07.20208702.
27. Asadi-Pooya AA, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, et al. Risk Factors Associated with Long COVID Syndrome: A Retrospective Study. *Iran J Med Sci*. 2021;46(6):428-36.
28. Moy FM, Hairi NN, Lim ERJ, Bulgiba A. Long COVID and its associated factors among COVID survivors in the community from a middle-income country-An online cross-sectional study. *PLoS One*. 2022;17(8):e0273364.
29. Rane MS, Robertson MM, Kulkarni SG, Frogel D, Gainus C, Nash D. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting. *Vaccine*. 2023;41(4):989-98.
30. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. *Jama*. 2022;327(11):1032-41.
31. Chanda D, Hines JZ, Itoh M, Fwoloshi S, Minchella PA, Zyambo KD, et al. COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021-2022. *Open Forum Infect Dis*. 2022;9(9):ofac469.

